Hypersensitivity to lamotrigine and nonaromatic anticonvulsant drugs: A review

Current Pharmaceutical Design

Volumn 14, Issue 27, 2008, Pages 2874-2882

  Gaeta, Francesco ^a,b   Alonzi, Cristiana ^a   Valluzzi, Rocco Luigi ^a   Viola, Marinella ^a   Elia, Maurizio ^c   Romano, Antonino ^a,c  

^a UCSC Allergy Unit   (Italy)

^b IRCCS Clinica Pineta Grande   (Italy)

^c OASI RESEARCH INSTITUTE IRCCS   (Italy)

Author keywords

Aromatic anticonvulsant; Cutaneous adverse reactions; Gabapentin; Hypersensitivity; Lamotrigine; Nonaromatic anticonvulsant; Topiramate; Valproate

Indexed keywords

CARBAMAZEPINE; GABAPENTIN; HLA B ANTIGEN; HLA B38 ANTIGEN; HLA DQ ANTIGEN; HLA DR ANTIGEN; INTERLEUKIN 5; LAMOTRIGINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; OXCARBAZEPINE; PHENYTOIN; RANTES; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROIC ACID;

ABSENCE; AMINOTRANSFERASE BLOOD LEVEL; ANTIGEN EXPRESSION; BIPOLAR DISORDER; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELLULAR IMMUNITY; CERVICAL LYMPHADENOPATHY; CONFUSION; DEPRESSION; DOSE KIDNEY FUNCTION RELATION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG ELIMINATION; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG POTENTIATION; DRUG STRUCTURE; DRUG WITHDRAWAL; ECZEMA; EOSINOPHILIA; EPILEPSY; ERYTHEMA; FOCAL EPILEPSY; HUMAN; LEUKOCYTE COUNT; LEUKOCYTOCLASTIC VASCULITIS; LEUKOPENIA; LIVER FAILURE; LOW DRUG DOSE; LYMPHADENOPATHY; LYMPHOCYTE TRANSFORMATION TEST; LYMPHOCYTOSIS; MACULOPAPULAR RASH; MULTIPLE ORGAN FAILURE; NAUSEA; NEUROPATHIC PAIN; NONHUMAN; PATCH TEST; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; PRURITUS; PSEUDOLYMPHOMA; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; SPLENOMEGALY; STEVENS JOHNSON SYNDROME; TONIC CLONIC SEIZURE; TOXIC EPIDERMAL NECROLYSIS; VOMITING;

ANIMALS; ANTICONVULSANTS; DRUG HYPERSENSITIVITY; HUMANS; SKIN TESTS; TRIAZINES;

EID: 65949091163     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208786369713     Document Type: Review

References (107)

1. Pichler WJ, Yawalkar N, Britschgi M, Depta J, Strasser I, Schmid S, et al. Cellular and molecular pathophysiology of cutaneous drug reactions. Am J Clin Dermatol 2002; 3: 229-38.
2. Zaccara G, Franciotta D, Perucca E. Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia 2007; 48: 1223-44.
3. Rzany B, Correia O, Kelly JP, Naldi L, Auquier A, Stern R. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: A case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions. Lancet 1999; 353: 2190-4.
4. Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology 2005; 64: 1134-8.
5. Bohan KH, Mansuri TF, Wilson NM. Anticonvulsant hypersensitivity syndrome: Implications for pharmaceutical care. Pharmacotherapy 2007; 27: 1425-39.
6. Schlienger RG, Shear NH. Antiepileptic drug hypersensitivity syndrome. Epilepsia 1998; 39: S3-7.
7. Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). Semin Cutan Med Surg 1996; 15: 250-257.
8. Naisbitt DJ, Farrell J, Wong G, Depta JP, Dodd CC, Hopkins JE, et al. Characterization of drug-specific T cells in lamotrigine hypersensitivity. J Allergy Clin Immunol 2003; 111: 1393-403.
9. Gogtay NJ, Bavdekar SB, Kshirsagar NA. Anticonvulsant hypersensitivity syndrome: A review. Expert Opin Drug Saf 2005; 4: 571-81.
10. Teraki Y, Murota H, Izaki S. Toxic epidermal necrolysis due to zonisamide associated with reactivation of human herpesvirus 6. Arch Dermatol 2008; 144: 232-5.
11. Descamps V, Valance A, Edlinger C, Fillet AM, Grossin M, Lebrun-Vignes B, et al. Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms. Arch Dermatol 2001; 137: 301-4.
12. Descamps V, Mahe E, Houhou N, Abramowitz L, Rozenberg F, Ranger-Rogez S, et al. Drug-induced hypersensitivity syndrome associated with Epstein-Barr virus infection. Br J Dermatol 2003; 48: 1032-4.
13. Torres MJ, Corzo JL, Leyva L, Mayorga C, Garcia-Martin FJ, Antunez C, et al. Differences in the immunological responses in drug- and virus-induced cutaneous reactions in children. Blood Cells Mol Dis 2003; 30: 124-31.
14. Kano Y, Inaoka M, Shiohara T. Association between anticonvulsant hypersensitivity syndrome and human herpesvirus 6 reactivation and hypogammaglobulinemia. Arch Dermatol 2004; 140: 183-8.
15. Brockow K, Romano A, Blanca M, Ring J, Pichler W, Demoly P. General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy 2002; 57: 45-51.
16. Nyfeler B, Pichler WJ. The lymphocyte transformation test for the diagnosis of drug allergy: Sensitivity and specificity. Clin Exp Allergy 1997; 27: 175-81.
17. Pichler WJ, Tilch J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy 2004; 59: 809-20.
18. Sachs B, Rönnau AC, Ruzicka T, Gleichmann E, Schuppe HC. Lamotrigine and toxic epidermal necrolysis. Lancet 1996; 348: 1597.
19. Schaub N, Bircher AJ. Severe hypersensitivity syndrome to lamotrigine confirmed by lymphocyte stimulation in vitro. Allergy 2000; 55: 191-3.
20. Romano A, Pettinato R, Andriolo M, Viola M, Guéant-Rodriguez RM, Valluzzi RL, et al. Hypersensitivity to aromatic anticonvulsants: in vivo and in vitro cross-reactivity studies. Curr Pharm Des 2006; 12: 3373-81.
21. Shear NH, Spielberg SP. Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk. J Clin Invest 1988; 82: 1826-32.
22. Aberer W, Bircher A, Romano A, Blanca M, Campi P, Fernandez J, et al. European Network for Drug Allergy (ENDA); EAACI interest group on drug hypersensitivity. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: General considerations. Allergy 2003; 58: 854-63.
23. Guberman AH, Besag FM, Brodie MJ, Dooley JM, Duchowny MS, Pellock JM, et al. Lamotrigine-associated rash: Risk/benefit considerations in adults and children. Epilepsia 1999; 40: 985-91.
24. Calabrese JR, Sullivan JR, Bowden CL, Suppes T, Goldberg JF, Sachs GS, et al. Rash in multicenter trials of lamotrigine in mood disorders: Clinical relevance and management. J Clin Psychiatry 2002; 63: 1012-9.
25. Bowden CL, Asnis GM, Ginsberg LD, Bentley B, Leadbetter R, White R. Safety and tolerability of lamotrigine for bipolar disorder. Drug Saf 2004; 27: 173-84.
26. Ketter TA, Greist JH, Graham JA, Roberts JN, Thompson TR, Nanry KP. The effect of dermatologic precautions on the incidence of rash with addition of lamotrigine in the treatment of bipolar I disorder: A randomized trial. J Clin Psychiatry 2006; 67: 400-6.
27. Richens A. Safety of lamotrigine. Epilepsia 1994; 35: S37-40.
28. Hirsch LJ, Weintraub DB, Buchsbaum R, Spencer HT, Straka T, Hager M, et al. Predictors of Lamotrigine-associated rash. Epilepsia 2006; 47: 318-22.
29. Alvestad S, Lydersen S, Brodtkorb E. Rash from antiepileptic drugs: influence by gender, age, and learning disability. Epilepsia 2007; 48: 1360-5.
30. Arif H, Buchsbaum R, Weintraub D, Koyfman S, Salas-Humara C, Bazil CW, et al. Comparison and predictors of rash associated with 15 antiepileptic drugs. Neurology 2007; 68: 1701-9.
31. Alvestad S, Lydersen S, Brodtkorb E. Cross-reactivity pattern of rash from current aromatic antiepileptic drugs. Epilepsy Res 2008; May 17.
32. Schlumberger E, Chavez F, Palacios L, Rey E, Pajot N, Dulac O. Lamotrigine in treatment of 120 children with epilepsy. Epilepsia 1994; 35: 359-67.
33. Fitton A, Goa KL. Lamotrigine. An update of its pharmacology and therapeutic use in epilepsy. Drugs 1995; 50: 691-713.
34. Messenheimer JA. Rash in adult and pediatric patients treated with lamotrigine. Can J Neurol Sci 1998; 25: S14-8.
35. Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 2008; 128: 35-44.
36. Naisbitt DJ, Williams DP, Pirmohamed M, Kitteringham NR, Park BK. Reactive metabolites and their role in drug reactions. Curr Opin Allergy Clin Immunol 2001; 1: 317-25.
37. Maggs JL, Naisbitt DJ, Tettey JN, Pirmohamed M, Park BK. Metabolism of lamotrigine to a reactive arene oxide intermediate. Chem Res Toxicol 2000; 13: 1075-81.
38. Anderson GD, Gidal BE, Messenheimer JA, Gilliam FG. Time course of lamotrigine de-induction: Impact of step-wise withdrawal of carbamazepine or phenytoin. Epilepsy Res 2002; 49: 211-7.
39. Lu W, Uetrecht JP. Possible bioactivation pathways of lamotrigine. Drug Metab Dispos 2007; 35: 1050-6.
40. Naisbitt DJ, Farrell J, Wong G, Depta JP, Dodd CC, Hopkins JE, et al. Characterization of drug-specific T cells in lamotrigine hypersensitivity. J Allergy Clin Immunol 2003; 111: 1393-403.
41. Pichler WJ. Pharmacological interaction of drugs with antigen-specific immune receptors: The p-i concept. Curr Opin Allergy Clin Immunol 2002; 2: 301-5.
42. Lonjou C, Borot N, Sekula P, Ledger N, Thomas L, Halevy S, et al. RegiSCAR study group. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 2008; 18: 99-107.
43. Tavernor SJ, Wong IC, Newton R, Brown SW. Rechallenge with lamotrigine after initial rash. Seizure 1995; 4: 67-71.
44. Besag FM, Ng GY, Pool F. Successful re-introduction of lamotrigine after initial rash. Seizure 2000; 9: 282-6.
45. P-Codrea Tigaran S, Sidenius P, Dam M. Lamotrigine-induced rash - worth a rechallenge. Acta Neurol Scand 2005; 111: 191-4.
46. Sterker M, Berrouschot J, Schneider D. Fatal course of toxic epidermal necrolysis under treatment with lamotrigine. Int J Clin Pharmacol Ther 1995; 33: 595-7.
47. Duval X, Chosidow O, Semah F, Lipsker D, Francès C, Herson S. Lamotrigine versus carbamazepine in epilepsy. Lancet 1995; 345: 1301-2.
48. Makin AJ, Fitt S, Williams R, Duncan JS. Fulminant hepatic failure induced by lamotrigine. BMJ 1995; 311: 292.
49. Campistol J, Geli M, Llistosella E, Molins J, Llobet M. Stevens-Johnson syndrome after lamotrigine treatment. Rev Neurol 1995; 23: 1236-8.
50. Dooley J, Camfield P, Gordon K, Camfield C, Wirrell Z, Smith E. Lamotrigine-induced rash in children. Neurology 1996; 46: 240-2.
51. Sullivan JR, Watson A. Lamotrigine-induced toxic epidermal necrolysis treated with intravenous cyclosporin: A discussion of pathogenesis and immunosuppressive management. Aus J Dermatol 1996; 37: 208-12.
52. Sachs B, Rönnau AC, Ruzicka T, Gleichmann E, Schuppe HC. Lamotrigine and toxic epidermal necrolysis. Lancet 1996; 348: 1597.
53. Wadelius M, Karlsson T, Wadelius C, Rane A. Lamotrigine and toxic epidermal necrolysis. Lancet 1996; 348: 1041.
54. Chaffin JJ, Davis SM. Suspected lamotrigine-induced toxic epidermal necrolysis. Ann Pharmacother 1997; 31: 720-3.
55. Chattergoon DS, McGuigan MA, Koren G, Hwang P, Ito S. Multiorgan dysfunction and disseminated intravascular coagulation in children receiving lamotrigine and valproic acid. Neurology 1997; 49: 1442-4
56. Iannetti P, Raucci U, Zuccaro P, Pacifici R. Lamotrigine hypersensitivity in childhood epilepsy. Epilepsia 1998; 39: 502-7.
57. Page RL 2nd, O'Neil MG, Yarbrough DR 3rd, Conradi S. Fatal toxic epidermal necrolysis related lamotrigine administration. Pharmacotherapy 1998; 18: 392-8.
58. Bocquet H, Farmer M, Bressieux JM, Barzegar C, Jullien M, Soto B, et al. Lyell syndrome and Stevens-Johnson syndrome caused by lamotrigine. Ann Dermatol Venereol 1999; 126: 46-8.
59. Brown TS, Appel JE, Kasteler JS, Callen JP. Hypersensitivity reaction in a child due to lamotrigine. Pediatr Dermatol 1999; 16: 46-9.
60. Gücüyener K, Türktaş I, Serdaroglu A, Ezgü FS. Suspected allergy to lamotrigine. Allergy 1999; 54: 767-8.
61. Sarris BM, Wong JG. Multisystem hypersensitivity reaction to lamotrigine. Neurology 1999; 53: 1367.
62. Fervenza FC, Kanakiriya S, Kunau RT, Gibney R, Lager DJ. Acute granulomatous interstitial nephritis and colitis in anticonvulsant hypersensitivity syndrome associated with lamotrigine treatment. Am J Kidney Dis 2000; 36: 1034-40.
63. Schaub N, Bircher AJ. Severe hypersensitivity syndrome to lamotrigine confirmed by lymphocyte stimulation in vitro. Allergy 2000; 55: 191-3.
64. Galindo PA, Borja J, Gómez E, Mur P, Gudín M, García R, et al. Anticonvulsant drug hypersensitivity. J Investig Allergol Clin Immunol 2002; 12: 299-304.
65. Overstreet K, Costanza C, Behling C, Hassanin T, Masliah E. Fatal progressive hepatic necrosis associated with lamotrigine treatment: A case report and literature review. Dig Dis Sci 2002; 47: 1921-5.
66. Sladden M, Mortimer N, Chave T. Toxic epidermal caused by lamotrigine. Aust Fam Physician 2004; 33: 829-30.
67. Rahman M, Haider N. Anticonvulsant hypersensitivity syndrome from addition of lamotrigine to divalproex. Am J Psychiatry 2005; 162: 1021.
68. Mansouri P, Rabiei M, Pourpak Z, Hallaji Z. Toxic epidermal necrolysis associated with concomitant use of lamotrigine and carbamazepine: A case report. Arch Dermatol 2005; 141: 788-9.
69. Karande S, Gogtay NJ, Kanchan S, Kshirsagar NA. Anticonvulsant hypersensitivity syndrome to lamotrigine confirmed by lymphocyte stimulation in vitro. Indian J Med Sci 2006; 60: 59-63.
70. Chang CC, Shiah IS, Chang HA, Huang SY. Toxic epidermal necrolysis with combination lamotrigine and valproate in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 147-50.
71. Chang CC, Shiah IS, Yeh CB, Wang TS, Chang HA. Lamotrigine-associated anticonvulsant hypersensitivity syndrome in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 741-4.
72. Parri N, Bernardini R, Pucci N, Novembre E, Azzari C, Vierucci A. Drug rash with eosinophilia and systemic symptoms induced by lamotrigine therapy. Int J Immunopathol Pharmacol 2007; 20: 643-5.
73. Kocak S, Girisgin SA, Gul M, Cander B, Kaya H, Kaya E. Stevens-Johnson syndrome due to concomitant use of lamotrigine and valproic acid. Am J Clin Dermatol 2007; 8: 107-11.
74. Melandri D. Lyell's syndrome skin lesions treated by Veloderm. J Eur Acad Dermatol Venereol. 2007; 21: 426-7.
75. Sahin S, Comert A, Akin O, Ayalp S, Karsidag S. Cutaneous drug eruptions by current antiepileptics: Case reports and alternative treatment options. Clin Neuropharmacol 2008; 31: 93-6.
76. Schlienger RG, Shapiro LE, Shear NH. Lamotrigine-induced severe cutaneous adverse reactions. Epilepsia 1998; 39: S22-6.
77. Lammintausta K, Kortekangas-Savolainen O. The usefulness of skin tests to prove drug hypersensitivity. Br J Dermatol 2005; 152: 968-74.
78. Egger J, Brett EM. Effects of sodium valproate in 100 children with special reference to weight. Br Med J (Clin Res Ed) 1981; 283: 577-81.
79. Nabi G. Exfoliative dermatitis (sodium valproate induced). Ann Saudi Med 1993; 13: 388-9.
80. Tennis P, Stern RS. Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: A record linkage study. Neurology 1997; 49: 542-6.
81. Li LM, Russo M, O'Donoghue MF, Duncan JS, Sander JW. Allergic skin rash with lamotrigine and concomitant valproate therapy: Evidence for an increased risk. Arq Neuropsiquiatr 1996; 54: 47-9.
82. Faught E, Morris G, Jacobson M, French J, Harden C, Montouris G, et al. Adding lamotrigine to valproate: Incidence of rash and other adverse effects. Postmarketing Antiepileptic Drug Survey (PADS) Group. Epilepsia 1999; 40: 1135-40.
83. Wong IC, Mawer GE, Sander JW. Factors influencing the incidence of lamotrigine-related skin rash. Ann Pharmacother 1999; 33: 1037-42.
84. Maganti R, Gidal BE, Shaw R, Rutecki P. Concomitant use of divalproex sodium and lamotrigine in developmentally disabled patients with epilepsy: A retrospective evaluation of efficacy and tolerability. Epilepsy Behav 2002; 3: 275-279.
85. Weintraub D, Buchsbaum R, Resor SR Jr, Hirsch LJ. The effect of antiepileptic drug co-medication on lamotrigine clearance. Arch Neurol 2005; 62: 1432-1436.
86. Osawa J, Naito S, Aihara M, Kitamura K, Ikezawa Z, Nakajima H. Evaluation of skin test reactions in patients with non-immediate type drug eruptions. J Dermatol 1990; 17: 235-9.
87. Conilleau V, Dompmartin A, Verneuil L, Michel M, Leroy D. Hypersensitivity syndrome due to 2 anticonvulsant drugs. Contact Dermatitis 1999; 41: 141-4.
88. Arévalo-Lorido JC, Carretero-Gómez J, Bureo-Dacal JC, Montero-Leal C, Bureo-Dacal P. Antiepileptic drug hypersensitivity syndrome in a patient treated with valproate. Br J Clin Pharmacol 2003; 55: 415-6.
89. Roepke S, Treudler R, Anghelescu I, Orfanos CE, Tebbe B. Valproic Acid and hypersensitivity syndrome. Am J Psychiatry 2004; 161: 579.
90. Cogrel O, Beylot-Barry M, Vergier B, Dubus P, Doutre MS, Merlio JP, et al. Sodium valproate-induced cutaneous pseudolymphoma followed by recurrence with carbamazepine. Br J Dermatol 2001; 144: 1235-8.
91. Huang YL, Hong HS, Wang ZW, Kuo TT. Fatal sodium valproate-induced hypersensitivity syndrome with lichenoid dermatitis and fulminant hepatitis. J Am Acad Dermatol 2003; 49: 316-9.
92. Wilton LV, Shakir S. A postmarketing surveillance study of gabapentin as add-on therapy for 3,100 patients in England. Epilepsia 2002; 43: 983-92.
93. De Toledo JC, Minagar A, Lowe MR, Ramsay RE. Skin eruption with gabapentin in a patient with repeated AED-induced Stevens-Johnson's syndrome. Ther Drug Monit 1999; 21: 137-8.
94. Ragucci MV, Cohen JM. Gabapentin-induced hypersensitivity syndrome. Clin Neuropharmacol 2001; 24: 103-5.
95. Poon DY, Law NM. A case of cutaneous leukocytoclastic vasculitis associated with gabapentin. Singapore Med J 2003; 44: 42-4.
96. Sahin S, Comert A, Akin O, Ayalp S, Karsidag S. Cutaneous drug eruptions by current antiepileptics: Case reports and alternative treatment options. Clin Neuropharmacol 2008; 31: 93-6.
97. Oskay T, Karademir A, Ertürk OI. Association of anticonvulsant hypersensitivity syndrome with Herpesvirus 6, 7. Epilepsy Res 2006; 70: 27-40.
98. Fletcher R, Butcher H, Raw J, Naqvi N. Gabapentin and hypersensitivity syndrome. J Postgrad Med 2007; 53: 276-7.
99. Reife R, Pledger G, Wu SC. Topiramate as add-on therapy: Pooled analysis of randomized controlled trials in adults. Epilepsia 2000; 41: S66-71.
100. Abou-Khalil B. Topiramate in the long-term management of refractory epilepsy. Topiramate YOL Study Group. Epilepsia 2000; 41: S72-6.
101. Mikaeloff Y, de Saint-Martin A, Mancini J, Peudenier S, Pedespan JM, Vallée L, et al. Topiramate: Efficacy and tolerability in children according to epilepsy syndromes. Epilepsy Res 2003; 53: 225-32.
102. Albsoul-Younes AM, Salem HA, Ajlouni SF, Al-Safi SA. Topiramate slow dose titration: Improved efficacy and tolerability. Pediatr Neurol 2004; 31: 349-52.
103. Ochoa JG. Pruritus, a rare but troublesome adverse reaction of topiramate. Seizure 2003; 12: 516-8.
104. Schiavino D, Nucera E, Buonomo A, Musumeci S, Pollastrini E, Roncallo C, et al. A case of type IV hypersensitivity to topiramate and carbamazepine. Contact Dermatitis 2005; 52: 161-2.
105. Duzova A, Bakkaloglu A. Central nervous system involvement in pediatric rheumatic diseases: Current concepts in treatment. Curr Pharm Des 2008; 14(13): 1295-301.
106. Sanna G, Bertolaccini ML, Khamashta MA. Neuropsychiatric involvement in systemic lupus erythematosus: Current therapeutic approach. Curr Pharm Des 2008; 14(13): 1261-9.
107. Thiry A, Dogne JM, Supuran CT, Masereel B. Anticonvulsant sulfonamides/ sulfamates/sulfamides with carbonic anhydrase inhibitory activity: Drug design and mechanism of action. Curr Pharm Des 2008; 14(7): 661-71.